US patent reform legislation may delay generics

Home/Policies & Legislation | Posted 06/05/2011 post-comment0 Post your comment

Generic drugmakers have been dealt a blow in Congress now that the Senate has passed patent-reform legislation despite efforts by the generics industry to remove a provision in the bill.

picture01

The America Invents Act, S23, was passed by the Senate on 8 March 2011, a major step forward for a bill that has been under consideration for several years and has reached the full Senate three times since 2008. The legislation overhauls the US patent system by changing it from a ‘first-to-invent’ to a ‘first-to-file’ system, and gives courts more influence in determining patent dispute damages, among other things.

Pharmaceutical Research and Manufacturers of America (PhRMA), the industry groups representing innovator companies, welcomed the decision saying that it represents a ‘commitment to innovation’.

However, the Generic Pharmaceutical Association (GPhA) is not too pleased. Their main issue is with section 11 of the bill, which relates to supplemental examination of patents. The GPhA is worried that this would allow a patent holder to ‘cleanse’ its patent, thus preventing patent challenges from generics manufacturers and delaying access to cheaper generic medicines.

The GPhA strongly supports current law and is urging the House to keep the current inequitable conduct provisions as they exist or improve the language currently in the bill. This, they believe, ‘will help preserve the duty of honesty and good faith that is essential to the proper functioning of the patent system’ and ‘will also help assure that affordable generics can come to the market.’

What happens next?

The bill was introduced to the House of Representatives on 30 March 2011 with a few small changes to the Senate version. It is believed that those few changes may, however, jeopardise the bill’s chances of being passed by the House this year.

Source: Genetic Engineering and Biotechnology News, GPhA, PhRMA

comment icon Comments (0)
Post your comment
Related content
Public consultation for the modification of the biosimilars regulation
02 AA010638
Home/Policies & Legislation Posted 16/01/2024
COFEPRIS promotes regulatory cooperation in the Americas
Latin America 1638px
Home/Policies & Legislation Posted 12/12/2023
ANVISA's decision on 'Skinny labels' for generics pending
Labelling V14I26
Home/Policies & Legislation Posted 14/11/2023
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010